Department of Clinical Medicine & Surgery, University of Naples Federico II, Naples, 80131, Italy.
Azienda Ospedaliera Universitaria San Giovanni di Dio Ruggi d'Aragona, Salerno, 84125, Italy.
Future Oncol. 2022 Jul;18(21):2643-2653. doi: 10.2217/fon-2021-1142. Epub 2022 May 24.
Comparison of first-line FOLFIRINOX (FFN) and nab-paclitaxel plus gemcitabine (NabGem) in patients with metastatic pancreatic ductal adenocarcinoma. The authors analyzed data from 160 patients with metastatic pancreatic adenocarcinoma receiving first-line FFN (n = 43) or NabGem (n = 117). FFN and NabGem were similar in median progression-free survival (24.43 vs 26.28 weeks; hazard ratio [HR]: 0.88) and medial overall survival (47.43 vs 42.86 weeks; HR: 0.90). Of the 43 patients receiving FFN, 26 (60.4%) were treated with second-line NabGem; 14/117 (12.0%) patients receiving NabGem received second-line FFN (p < 0.0001). In the FFN → NabGem and NabGem → FFN groups, median overall survival was 51.2 and 71.6 weeks (HR: 0.69; p = 0.15). In patients receiving NabGem, second-line FFN, compared with FOLFOX/CAPOX or FOLFIRI, improved median progression-free survival 2 (25.6 vs 12.1 weeks; HR: 0.47; p = 0.0067) and median overall survival 2 (39.0 vs 19.14 weeks; HR: 0.49; p = 0.032). First-line FFN and NabGem promote similar clinical outcomes. Second-line FFN should be considered after NabGem.
比较转移性胰腺导管腺癌患者的一线 FOLFIRINOX（FFN）和 nab-紫杉醇联合吉西他滨（NabGem）。作者分析了 160 名接受一线 FFN（n=43）或 NabGem（n=117）治疗的转移性胰腺腺癌患者的数据。FFN 和 NabGem 在中位无进展生存期（24.43 与 26.28 周；风险比[HR]：0.88）和中位总生存期（47.43 与 42.86 周；HR：0.90）方面相似。在接受 FFN 的 43 名患者中，有 26 名（60.4%）接受了二线 NabGem 治疗；在接受 NabGem 的 117 名患者中有 14 名（12.0%）接受了二线 FFN（p<0.0001）。在 FFN→NabGem 和 NabGem→FFN 组中，中位总生存期分别为 51.2 和 71.6 周（HR：0.69；p=0.15）。在接受 NabGem 的患者中，与 FOLFOX/CAPOX 或 FOLFIRI 相比，二线 FFN 改善了中位无进展生存期 2（25.6 与 12.1 周；HR：0.47；p=0.0067）和中位总生存期 2（39.0 与 19.14 周；HR：0.49；p=0.032）。一线 FFN 和 NabGem 促进了相似的临床结局。在 NabGem 之后应考虑二线 FFN。
